Resumen

VELAZQUEZ-GUADARRAMA, Norma et al. Resistance to linezolid in methicillin-resistant Staphylococcus aureus and Enterococcus with high-level resistance to aminoglycosides in a third-level pediatric hospital. Bol. Med. Hosp. Infant. Mex. [online]. 2010, vol.67, n.1, pp.19-26. ISSN 1665-1146.

Background: The emergence of resistance to the oxazolidinones by methicillin-resistant Staphylococcus aureus (MRSA) and high-level aminoglycoside-resistant (HLRA) Enterococcus spp not exposed is one of the main reasons for control of the clinical use of these antibiotics. Methods: We studied 95 strains of MRSA and HLAR, which were isolated from January 2003 to December 2007 at the Hospital Infantil de México Federico Gómez. The strains were identified by conventional tests. Antimicrobial susceptibility was evaluated for several antimicrobial agents including linezolid according to the Clinical and Laboratory Standards Institute (CLSI). The high resistance to aminoglycosides was tested by amplification of genes aac (6')-/e, aph (2")-and ant (6') in enterococci. Staphylococcal cassette chromosomal mec (SCCmec) associated with MRSA was identified by molecular techniques described previously. Results: All MRSA strains showed SCCmec type II, and 100% of enterococci strains with phenotype HLAR showed genes associated with high-level aminoglycoside resistance; 12% of HLAR enterococci strains showed intermediate values to linezolid (MIC 4 μg/mL) and only one strain was resistant (MIC 128 μg/mL). Of the MRSA strains, 2.2% were resistant to linezolid (MIC 8 μg/mL). Conclusion: Linezolid is a clinically valuable option as a form of therapy. However, continuous surveillance is necessary to determine the emergent risk of resistance strains and to establish guidelines for appropriate use.

Palabras llave : linezolid; methicillin-resistant Staphylococcus aureus; high-level-resistant aminoglycosides.

        · resumen en Español     · texto en Español     · Español ( pdf )